F.D.A. Rejects Closely Watched Lung Cancer Drug From China
The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
